Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Change in Cash: 2023-2025

Historic Change in Cash for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to -$24.4 million.

  • NewAmsterdam Pharma Co N.V's Change in Cash fell 94.67% to -$24.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.1 million, marking a year-over-year increase of 133.22%. This contributed to the annual value of $438.1 million for FY2024, which is 431.06% up from last year.
  • NewAmsterdam Pharma Co N.V's Change in Cash amounted to -$24.4 million in Q3 2025, which was up 87.40% from -$193.4 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Change in Cash ranged from a high of $357.0 million in Q4 2024 and a low of -$193.4 million during Q2 2025.
  • For the 3-year period, NewAmsterdam Pharma Co N.V's Change in Cash averaged around $5.5 million, with its median value being -$27.1 million (2025).
  • Its Change in Cash has fluctuated over the past 5 years, first skyrocketed by 1,179.15% in 2024, then slumped by 290.43% in 2025.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's Change in Cash (Quarterly) stood at -$33.1 million in 2023, then surged by 1,179.15% to $357.0 million in 2024, then crashed by 94.67% to -$24.4 million in 2025.
  • Its Change in Cash stands at -$24.4 million for Q3 2025, versus -$193.4 million for Q2 2025 and -$27.1 million for Q1 2025.